Mingyue Cai

1.6k total citations · 1 hit paper
53 papers, 1.1k citations indexed

About

Mingyue Cai is a scholar working on Hepatology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Mingyue Cai has authored 53 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hepatology, 13 papers in Pathology and Forensic Medicine and 11 papers in Surgery. Recurrent topics in Mingyue Cai's work include Hepatocellular Carcinoma Treatment and Prognosis (19 papers), Cancer Mechanisms and Therapy (11 papers) and Liver Disease Diagnosis and Treatment (9 papers). Mingyue Cai is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (19 papers), Cancer Mechanisms and Therapy (11 papers) and Liver Disease Diagnosis and Treatment (9 papers). Mingyue Cai collaborates with scholars based in China, United States and Hong Kong. Mingyue Cai's co-authors include Kangshun Zhu, Wensou Huang, Liteng Lin, Yongjian Guo, Jingjun Huang, Xintao Shuai, Yong Wang, Licong Liang, Jingwen Zhou and Lisha Lai and has published in prestigious journals such as Journal of Clinical Oncology, Biomaterials and Advanced Functional Materials.

In The Last Decade

Mingyue Cai

49 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study

2022 117 citations Mingyue Cai, Wensou Huang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mingyue Cai China	18	530	256	206	195	187	53	1.1k
Wensou Huang China	17	585 1.1×	293 1.1×	166 0.8×	232 1.2×	83 0.4×	44	981
Guanghua Rong China	17	333 0.6×	250 1.0×	211 1.0×	200 1.0×	160 0.9×	27	1.1k
Liteng Lin China	18	280 0.5×	151 0.6×	368 1.8×	110 0.6×	268 1.4×	39	1.1k
Zuojin Liu China	17	200 0.4×	211 0.8×	434 2.1×	287 1.5×	110 0.6×	63	1.3k
Xiaofeng Zhang China	20	355 0.7×	168 0.7×	362 1.8×	152 0.8×	98 0.5×	44	1.2k
Qichang Zheng China	19	199 0.4×	349 1.4×	509 2.5×	200 1.0×	100 0.5×	43	1.5k
Yitao Ding China	20	218 0.4×	129 0.5×	434 2.1×	573 2.9×	111 0.6×	52	1.3k
Zifang Song China	20	156 0.3×	335 1.3×	544 2.6×	162 0.8×	359 1.9×	47	1.5k
Yu Wen China	9	168 0.3×	94 0.4×	168 0.8×	123 0.6×	111 0.6×	17	622
Jiaming Lai China	17	249 0.5×	155 0.6×	484 2.3×	286 1.5×	42 0.2×	57	1.1k

Countries citing papers authored by Mingyue Cai

Since Specialization

Citations

This map shows the geographic impact of Mingyue Cai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingyue Cai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingyue Cai more than expected).

Fields of papers citing papers by Mingyue Cai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingyue Cai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingyue Cai. The network helps show where Mingyue Cai may publish in the future.

Co-authorship network of co-authors of Mingyue Cai

This figure shows the co-authorship network connecting the top 25 collaborators of Mingyue Cai. A scholar is included among the top collaborators of Mingyue Cai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingyue Cai. Mingyue Cai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Jingwen, Jingjun Huang, Yongjian Guo, et al.. (2025). Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study. ImmunoTargets and Therapy. Volume 14. 1187–1200.

Lü, Yabin, et al.. (2025). Epidemiological Patterns of Gastrointestinal Parasitic Infections in Equine Populations from Urumqi and Ili, Xinjiang, China. Veterinary Sciences. 12(7). 644–644.

Chen, Gengjia, Liteng Lin, Bo Li, et al.. (2024). Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy. Biomaterials. 309. 122626–122626. 13 indexed citations

Li, Rui, Zhile Liu, Wensou Huang, et al.. (2024). Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension. Cellular and Molecular Gastroenterology and Hepatology. 18(4). 101379–101379. 2 indexed citations

Cai, Mingyue, Wensou Huang, Wei Liang, et al.. (2024). Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study. Liver International. 44(4). 920–930. 13 indexed citations

Cai, Mingyue, Licong Liang, Jian Zhang, et al.. (2024). Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study. International Journal of Surgery. 110(12). 7860–7870. 9 indexed citations

Cai, Mingyue, Liping Liang, Hui Chen, et al.. (2024). 975P Lenvatinib plus drug-eluting bead transarterial chemoembolization with or without hepatic arterial infusion chemotherapy for hepatocellular carcinoma (> 7 cm) with portal vein tumor thrombosis: A retrospective multicenter cohort study. Annals of Oncology. 35. S668–S668. 1 indexed citations

Hu, Beibei, Pingping Liang, Xinyue Li, et al.. (2023). Advances in molecularly imprinted polymers-based electrochemical sensors for the detection of gonadal steroid hormones. TrAC Trends in Analytical Chemistry. 171. 117485–117485. 12 indexed citations

Liu, Mingyu, Lulu Xie, Yuying Zhang, et al.. (2023). Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases. Cell Death and Disease. 14(1). 25–25. 18 indexed citations

10.

Chen, Ye, Weiguo Cai, Mingyue Cai, et al.. (2023). Intratumoral Lactate Depletion Based on Injectable Nanoparticles−Hydrogel Composite System Synergizes with Immunotherapy against Postablative Hepatocellular Carcinoma Recurrence. Advanced Healthcare Materials. 13(6). e2303031–e2303031. 17 indexed citations

11.

Chen, Ye, Qianbing Zhang, Xiaobin Wang, et al.. (2023). HBV suppresses macrophage immune responses by impairing the TCA cycle through the induction of CS/PDHC hyperacetylation. Hepatology Communications. 7(11). 11 indexed citations

12.

Wang, Xiaobin, Qiaoyun Zhang, Jingwen Zhou, et al.. (2023). T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 11(2). e006493–e006493. 17 indexed citations

13.

Xie, Lulu, Mingyu Liu, Mingyue Cai, et al.. (2023). Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma. Biomedicine & Pharmacotherapy. 159. 114254–114254. 15 indexed citations

14.

Chen, Ye, Mingyu Liu, Jingjun Huang, et al.. (2021). Sublethal heat stress-induced O-GlcNAcylation coordinates the Warburg effect to promote hepatocellular carcinoma recurrence and metastasis after thermal ablation. Cancer Letters. 518. 23–34. 42 indexed citations

15.

Huang, Jingjun, Wensou Huang, Meixiao Zhan, et al.. (2021). Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 8. 1445–1458. 27 indexed citations

16.

Cai, Mingyue, Bo Li, Liteng Lin, et al.. (2020). A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. Biomaterials Science. 8(12). 3485–3499. 31 indexed citations

17.

Lin, Liteng, Rui Li, Jingjun Huang, et al.. (2020). Nanodrug with ROS and pH Dual‐Sensitivity Ameliorates Liver Fibrosis via Multicellular Regulation. Advanced Science. 7(7). 1903138–1903138. 80 indexed citations

18.

Pang, Tao, et al.. (2019). Regulation of phase structure, upconversion luminescence and thermal property of NaYF4:Yb3+,Ho3+,Ce3+ through doping concentration of Ce3+ and Yb3+. Journal of Alloys and Compounds. 789. 904–909. 12 indexed citations

19.

Lin, Liteng, Rui Li, Mingyue Cai, et al.. (2018). Andrographolide Ameliorates Liver Fibrosis in Mice: Involvement of TLR4/NF‐κB and TGF‐β1/Smad2 Signaling Pathways. Oxidative Medicine and Cellular Longevity. 2018(1). 7808656–7808656. 48 indexed citations

20.

Cai, Mingyue, Wensou Huang, Chaoshuang Lin, et al.. (2015). Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications. European Radiology. 26(2). 370–380. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact